TW201717952A - 含有環狀二肽的血清肉鹼分解酵素阻礙用組成物 - Google Patents

含有環狀二肽的血清肉鹼分解酵素阻礙用組成物 Download PDF

Info

Publication number: TW201717952A
Authority: TW; Taiwan
Prior art keywords: cyclo; carnitine; ile; dipeptidase; tyr
Prior art date: 2015-07-16

Application number

TW105122442A

Other languages

English (en)

Chinese (zh)

Inventor

Shinya Fukizawa

Hiroshi Watanabe

Keiichi Abe

Original Assignee

Suntory Holdings Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-16

Filing date

2016-07-15

Publication date

2017-06-01

2016-07-15 Application filed by Suntory Holdings Ltd filed Critical Suntory Holdings Ltd

2017-06-01 Publication of TW201717952A publication Critical patent/TW201717952A/zh

Links

108010016626 Dipeptides Proteins 0.000 title claims abstract description 119
239000000203 mixture Substances 0.000 title claims abstract description 94
102100031006 Beta-Ala-His dipeptidase Human genes 0.000 title abstract description 53
101000919694 Homo sapiens Beta-Ala-His dipeptidase Proteins 0.000 title description 10
150000003839 salts Chemical class 0.000 claims abstract description 70
230000002401 inhibitory effect Effects 0.000 claims abstract description 59
238000000034 method Methods 0.000 claims abstract description 35
230000002265 prevention Effects 0.000 claims abstract description 21
230000003920 cognitive function Effects 0.000 claims abstract description 17
PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 141
229960004203 carnitine Drugs 0.000 claims description 135
125000004122 cyclic group Chemical group 0.000 claims description 108
102000003850 Dipeptidase 1 Human genes 0.000 claims description 76
108090000204 Dipeptidase 1 Proteins 0.000 claims description 76
108090000765 processed proteins & peptides Proteins 0.000 claims description 50
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 27
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 26
230000006872 improvement Effects 0.000 claims description 22
239000004472 Lysine Substances 0.000 claims description 21
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 20
239000002253 acid Substances 0.000 claims description 20
239000004480 active ingredient Substances 0.000 claims description 20
XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 17
229940086555 cyclomethicone Drugs 0.000 claims description 17
208000024827 Alzheimer disease Diseases 0.000 claims description 16
UWBDLNOCIDGPQE-GUBZILKMSA-N Ile-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN UWBDLNOCIDGPQE-GUBZILKMSA-N 0.000 claims description 16
DRCKHKZYDLJYFQ-YWIQKCBGSA-N Ile-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DRCKHKZYDLJYFQ-YWIQKCBGSA-N 0.000 claims description 16
206010012601 diabetes mellitus Diseases 0.000 claims description 16
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 16
CUVKAUWOMPJEMI-ROUUACIJSA-N (11S,14S)-Cyclo-(L-Trp-L-Phe) Chemical compound C([C@@H]1NC([C@@H](NC1=O)CC=1C2=CC=CC=C2NC=1)=O)C1=CC=CC=C1 CUVKAUWOMPJEMI-ROUUACIJSA-N 0.000 claims description 15
235000001014 amino acid Nutrition 0.000 claims description 15
229940024606 amino acid Drugs 0.000 claims description 15
150000001413 amino acids Chemical class 0.000 claims description 15
QYLJIYOGHRGUIH-CIUDSAMLSA-N Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N QYLJIYOGHRGUIH-CIUDSAMLSA-N 0.000 claims description 14
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 14
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 14
-1 Phenylaminotryptophanic acid Chemical compound 0.000 claims description 14
201000010099 disease Diseases 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
230000036542 oxidative stress Effects 0.000 claims description 14
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 claims description 14
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 13
WEDDFMCSUNNZJR-WDSKDSINSA-N Met-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(O)=O WEDDFMCSUNNZJR-WDSKDSINSA-N 0.000 claims description 13
210000004204 blood vessel Anatomy 0.000 claims description 13
230000036737 immune function Effects 0.000 claims description 13
ZJDMXAAEAVGGSK-ROUUACIJSA-N (3s,6s)-3-[(4-hydroxyphenyl)methyl]-6-(1h-indol-3-ylmethyl)piperazine-2,5-dione Chemical compound C1=CC(O)=CC=C1C[C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N1 ZJDMXAAEAVGGSK-ROUUACIJSA-N 0.000 claims description 12
GENSLUDVKWKQMX-STQMWFEESA-N (3s,6s)-3-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)piperazine-2,5-dione Chemical compound N1C(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CC1=CC=C(O)C=C1 GENSLUDVKWKQMX-STQMWFEESA-N 0.000 claims description 12
GENSLUDVKWKQMX-UHFFFAOYSA-N 9-Acetyl-10-deacetylspicataxine Natural products N1C(=O)C(CC(C)C)NC(=O)C1CC1=CC=C(O)C=C1 GENSLUDVKWKQMX-UHFFFAOYSA-N 0.000 claims description 12
206010003805 Autism Diseases 0.000 claims description 12
208000020706 Autistic disease Diseases 0.000 claims description 12
KDAHZWKHYACWHQ-XDTLVQLUSA-N Cyclo-(Leu-Tyr) Natural products O=C1[C@H]([C@H](CC)C)NC(=O)[C@H](Cc2ccc(O)cc2)N1 KDAHZWKHYACWHQ-XDTLVQLUSA-N 0.000 claims description 12
YBAFDPFAUTYYRW-YUMQZZPRSA-N Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O YBAFDPFAUTYYRW-YUMQZZPRSA-N 0.000 claims description 12
KTGFOCFYOZQVRJ-ZKWXMUAHSA-N Ile-Glu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O KTGFOCFYOZQVRJ-ZKWXMUAHSA-N 0.000 claims description 12
MUFXDFWAJSPHIQ-XDTLVQLUSA-N Ile-Tyr Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 MUFXDFWAJSPHIQ-XDTLVQLUSA-N 0.000 claims description 12
206010061218 Inflammation Diseases 0.000 claims description 12
NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 claims description 12
BJFJQOMZCSHBMY-YUMQZZPRSA-N Met-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O BJFJQOMZCSHBMY-YUMQZZPRSA-N 0.000 claims description 12
YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 claims description 12
108010030615 cyclo(leucyl-tyrosyl) Proteins 0.000 claims description 12
ZJDMXAAEAVGGSK-UHFFFAOYSA-N cyclo-L-Trp-L-Phe Natural products C1=CC(O)=CC=C1CC1C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)N1 ZJDMXAAEAVGGSK-UHFFFAOYSA-N 0.000 claims description 12
235000013922 glutamic acid Nutrition 0.000 claims description 12
239000004220 glutamic acid Substances 0.000 claims description 12
230000004054 inflammatory process Effects 0.000 claims description 12
108010044374 isoleucyl-tyrosine Proteins 0.000 claims description 12
108010054155 lysyllysine Proteins 0.000 claims description 12
238000004519 manufacturing process Methods 0.000 claims description 12
HXWUJJADFMXNKA-BQBZGAKWSA-N Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O HXWUJJADFMXNKA-BQBZGAKWSA-N 0.000 claims description 11
210000004369 blood Anatomy 0.000 claims description 11
239000008280 blood Substances 0.000 claims description 11
230000003247 decreasing effect Effects 0.000 claims description 11
230000036252 glycation Effects 0.000 claims description 11
KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 11
JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 claims description 10
GVRKWABULJAONN-VQVTYTSYSA-N Val-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVRKWABULJAONN-VQVTYTSYSA-N 0.000 claims description 10
NGPCLOGFGKJCBP-UHFFFAOYSA-N cYY Natural products C1=CC(O)=CC=C1CC1C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)N1 NGPCLOGFGKJCBP-UHFFFAOYSA-N 0.000 claims description 10
NGPCLOGFGKJCBP-HOTGVXAUSA-N cyclo(L-tyrosyl-L-tyrosyl) Chemical compound C1=CC(O)=CC=C1C[C@H]1C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1 NGPCLOGFGKJCBP-HOTGVXAUSA-N 0.000 claims description 10
108010053287 cyclo(tyrosyl-tyrosyl) Proteins 0.000 claims description 10
108010073969 valyllysine Proteins 0.000 claims description 10
239000000470 constituent Substances 0.000 claims description 9
229960000310 isoleucine Drugs 0.000 claims description 9
NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 claims description 8
230000009467 reduction Effects 0.000 claims description 8
150000001412 amines Chemical class 0.000 claims description 6
230000006870 function Effects 0.000 claims description 6
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
150000003573 thiols Chemical class 0.000 claims description 6
DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 claims description 6
230000003078 antioxidant effect Effects 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
239000004473 Threonine Substances 0.000 claims description 4
YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 3
238000012423 maintenance Methods 0.000 claims description 3
229960003732 tyramine Drugs 0.000 claims description 3
230000035882 stress Effects 0.000 claims description 2
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 2
UAELJFMKOJFPRX-VKHMYHEASA-N (2s)-2-(sulfonylamino)pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)N=S(=O)=O UAELJFMKOJFPRX-VKHMYHEASA-N 0.000 claims 1
102100025840 Coiled-coil domain-containing protein 86 Human genes 0.000 claims 1
101000932708 Homo sapiens Coiled-coil domain-containing protein 86 Proteins 0.000 claims 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
229940009098 aspartate Drugs 0.000 claims 1
150000001924 cycloalkanes Chemical class 0.000 claims 1
LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims 1
RSPCKAHMRANGJZ-UHFFFAOYSA-N thiohydroxylamine Chemical compound SN RSPCKAHMRANGJZ-UHFFFAOYSA-N 0.000 claims 1
101710192841 Beta-Ala-His dipeptidase Proteins 0.000 abstract description 44
230000007423 decrease Effects 0.000 abstract description 5
229940123756 carnosine dipeptidase 1 inhibitor Drugs 0.000 abstract 1
230000001747 exhibiting effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 description 42
102000004190 Enzymes Human genes 0.000 description 24
108090000790 Enzymes Proteins 0.000 description 24
239000000047 product Substances 0.000 description 22
241000196324 Embryophyta Species 0.000 description 17
235000013305 food Nutrition 0.000 description 16
238000010438 heat treatment Methods 0.000 description 16
210000002966 serum Anatomy 0.000 description 16
230000005764 inhibitory process Effects 0.000 description 15
210000001519 tissue Anatomy 0.000 description 15
102100031007 Cytosolic non-specific dipeptidase Human genes 0.000 description 14
101000919690 Homo sapiens Cytosolic non-specific dipeptidase Proteins 0.000 description 14
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 13
244000269722 Thea sinensis Species 0.000 description 11
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 10
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 10
238000002360 preparation method Methods 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 9
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 8
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 8
CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 8
239000000243 solution Substances 0.000 description 8
QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 7
108010087806 Carnosine Proteins 0.000 description 7
108010035532 Collagen Proteins 0.000 description 7
102000008186 Collagen Human genes 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 7
229940044199 carnosine Drugs 0.000 description 7
229920001436 collagen Polymers 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
210000002826 placenta Anatomy 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
235000010469 Glycine max Nutrition 0.000 description 6
230000009471 action Effects 0.000 description 6
239000000872 buffer Substances 0.000 description 6
238000000354 decomposition reaction Methods 0.000 description 6
235000015872 dietary supplement Nutrition 0.000 description 6
235000013402 health food Nutrition 0.000 description 6
239000002994 raw material Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
102000004860 Dipeptidases Human genes 0.000 description 5
108090001081 Dipeptidases Proteins 0.000 description 5
244000068988 Glycine max Species 0.000 description 5
239000011575 calcium Substances 0.000 description 5
229910052791 calcium Inorganic materials 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
239000002537 cosmetic Substances 0.000 description 5
230000037406 food intake Effects 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
230000003169 placental effect Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
241000124008 Mammalia Species 0.000 description 4
229940000635 beta-alanine Drugs 0.000 description 4
235000013361 beverage Nutrition 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
235000013376 functional food Nutrition 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000012552 review Methods 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
CUQGPVWDPNMQEZ-ZDUSSCGKSA-N (2s)-2-(decylamino)pentanedioic acid Chemical compound CCCCCCCCCCN[C@H](C(O)=O)CCC(O)=O CUQGPVWDPNMQEZ-ZDUSSCGKSA-N 0.000 description 3
102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
240000005979 Hordeum vulgare Species 0.000 description 3
235000007340 Hordeum vulgare Nutrition 0.000 description 3
LBRGFJHYSJHUTD-FIZIFZEPSA-N N[C@@H](CCCCN)C(=O)O.C1(CCCCC1)N[C@@H](CCCCN)C(=O)O Chemical compound N[C@@H](CCCCN)C(=O)O.C1(CCCCC1)N[C@@H](CCCCN)C(=O)O LBRGFJHYSJHUTD-FIZIFZEPSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
108010046377 Whey Proteins Proteins 0.000 description 3
102000007544 Whey Proteins Human genes 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000000605 extraction Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
235000013336 milk Nutrition 0.000 description 3
239000008267 milk Substances 0.000 description 3
210000004080 milk Anatomy 0.000 description 3
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
PHIQHXFUZVPYII-LURJTMIESA-N (S)-carnitine Chemical compound C[N+](C)(C)C[C@@H](O)CC([O-])=O PHIQHXFUZVPYII-LURJTMIESA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 2
VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 2
201000006474 Brain Ischemia Diseases 0.000 description 2
102000011632 Caseins Human genes 0.000 description 2
108010076119 Caseins Proteins 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
206010008120 Cerebral ischaemia Diseases 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
229940123426 Dipeptidase 1 inhibitor Drugs 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
102000014171 Milk Proteins Human genes 0.000 description 2
108010011756 Milk Proteins Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
239000005862 Whey Substances 0.000 description 2
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000002567 autonomic effect Effects 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000005018 casein Substances 0.000 description 2
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
235000021240 caseins Nutrition 0.000 description 2
230000030833 cell death Effects 0.000 description 2
206010008118 cerebral infarction Diseases 0.000 description 2
230000009920 chelation Effects 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
235000013373 food additive Nutrition 0.000 description 2
239000002778 food additive Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
201000001421 hyperglycemia Diseases 0.000 description 2
230000002519 immonomodulatory effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229910021645 metal ion Inorganic materials 0.000 description 2
235000021239 milk protein Nutrition 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
230000035699 permeability Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000001766 physiological effect Effects 0.000 description 2
201000000980 schizophrenia Diseases 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000013589 supplement Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
229950009811 ubenimex Drugs 0.000 description 2
GXQVBUWKEVQSPN-VKHMYHEASA-N (5s)-5-amino-2,2-dioxo-1,3,2-dioxathiocane-4,8-dione Chemical compound N[C@H]1CCC(=O)OS(=O)(=O)OC1=O GXQVBUWKEVQSPN-VKHMYHEASA-N 0.000 description 1
ANRUJJLGVODXIK-UHFFFAOYSA-N 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide Chemical compound NCCC(=O)NCCC1=CN=CN1 ANRUJJLGVODXIK-UHFFFAOYSA-N 0.000 description 1
LUMNWCHHXDUKFI-UHFFFAOYSA-N 5-bicyclo[2.2.1]hept-2-enylmethanol Chemical compound C1C2C(CO)CC1C=C2 LUMNWCHHXDUKFI-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
ROWCTNFEMKOIFQ-YUMQZZPRSA-N Arg-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N ROWCTNFEMKOIFQ-YUMQZZPRSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
241000037488 Coccoloba pubescens Species 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
YIWFXZNIBQBFHR-LURJTMIESA-N Gly-His Chemical compound [NH3+]CC(=O)N[C@H](C([O-])=O)CC1=CN=CN1 YIWFXZNIBQBFHR-LURJTMIESA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
240000003553 Leptospermum scoparium Species 0.000 description 1
235000015459 Lycium barbarum Nutrition 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
UASDAHIAHBRZQV-YUMQZZPRSA-N Met-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N UASDAHIAHBRZQV-YUMQZZPRSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
102000004472 Myostatin Human genes 0.000 description 1
108010056852 Myostatin Proteins 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
XIGOXAVTSJEKFW-NXMISADUSA-N N[C@@H](CCCCN)C(=O)O.C1(CCCCCCCCC1)N[C@@H](CCCCN)C(=O)O Chemical compound N[C@@H](CCCCN)C(=O)O.C1(CCCCCCCCC1)N[C@@H](CCCCN)C(=O)O XIGOXAVTSJEKFW-NXMISADUSA-N 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
206010058667 Oral toxicity Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108010064851 Plant Proteins Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000288906 Primates Species 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
239000004365 Protease Substances 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108010073771 Soybean Proteins Proteins 0.000 description 1
235000006468 Thea sinensis Nutrition 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
TYYLDKGBCJGJGW-WMZOPIPTSA-N Trp-Tyr Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=C(O)C=C1 TYYLDKGBCJGJGW-WMZOPIPTSA-N 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003064 anti-oxidating effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
108700021352 carcinine Proteins 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000000701 coagulant Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000012937 correction Methods 0.000 description 1
TXGVDTJWMZUNMP-UHFFFAOYSA-N cyclodecanamine Chemical compound NC1CCCCCCCCC1 TXGVDTJWMZUNMP-UHFFFAOYSA-N 0.000 description 1
UCZUCGRGTXIWLR-UHFFFAOYSA-N cyclohexyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1CCCCC1 UCZUCGRGTXIWLR-UHFFFAOYSA-N 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
235000021245 dietary protein Nutrition 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000035622 drinking Effects 0.000 description 1
230000009982 effect on human Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
238000000227 grinding Methods 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
102000049010 human CNDP1 Human genes 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229910017053 inorganic salt Inorganic materials 0.000 description 1
238000011835 investigation Methods 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
244000144972 livestock Species 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229940049920 malate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
210000004993 mammalian placenta Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229940127554 medical product Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
235000008935 nutritious Nutrition 0.000 description 1
231100000418 oral toxicity Toxicity 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
229940075930 picrate Drugs 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical group O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 1
235000021118 plant-derived protein Nutrition 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
239000012264 purified product Substances 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000019710 soybean protein Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
108010044292 tryptophyltyrosine Proteins 0.000 description 1
230000035899 viability Effects 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
235000021119 whey protein Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

TW105122442A 2015-07-16 2016-07-15 含有環狀二肽的血清肉鹼分解酵素阻礙用組成物 TW201717952A (zh)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2015142091		2015-07-16

Publications (1)

Publication Number	Publication Date
TW201717952A true TW201717952A (zh)	2017-06-01

Family

ID=57757507

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW105122442A TW201717952A (zh)	2015-07-16	2016-07-15	含有環狀二肽的血清肉鹼分解酵素阻礙用組成物

Country Status (3)

Country	Link
JP (1)	JP6669750B2 (fr)
TW (1)	TW201717952A (fr)
WO (1)	WO2017010537A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW201733608A (zh) *	2016-01-08	2017-10-01	Suntory Holdings Ltd	含有環狀二肽之神經性疾病之預防用組成物
CN108546250B (zh) *	2018-04-04	2021-06-11	南京农业大学	环-l-谷氨酸-l-亮氨酸及其应用
WO2023120405A1 (fr) *	2021-12-23	2023-06-29	サントリーホールディングス株式会社	COMPOSITION POUR RÉDUIRE AU MAXIMUM LA PRODUCTION ET/OU L'ACCUMULATION DE β-AMYLOÏDE
WO2023120407A1 (fr) *	2021-12-23	2023-06-29	サントリーホールディングス株式会社	COMPOSITION POUR SUPPRIMER LA PRODUCTION ET/OU L'ACCUMULATION DE β-AMYLOÏDE
AU2022420239A1 (en) *	2021-12-23	2024-07-11	Suntory Holdings Limited	Composition for suppressing or ameliorating cognitive function decline
WO2024262349A1 (fr) *	2023-06-19	2024-12-26	サントリーホールディングス株式会社	COMPOSITION POUR SUPPRIMER OU AMÉLIORER LA DÉTÉRIORATION DE LA FONCTION COGNITIVE, ET COMPOSITION POUR INHIBER LA β-SÉCRÉTASE
CN117122667B (zh) *	2023-10-26	2024-12-06	中国海洋大学	小分子肽fw在制备缓解阿尔茨海默症的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004064866A1 (fr) *	2003-01-20	2004-08-05	Innovative Vision Products, Inc.	Utilisation combinee d'un inhibiteur de carnosinase presentant des l-carnosines et composition associee
JP5576653B2 (ja) *	2008-12-26	2014-08-20	サントリー食品インターナショナル株式会社	環状ジペプチド含有飲料
HK1215797A1 (zh) *	2014-06-20	2016-09-15	三得利控股株式会社	尿酸值下降剂

2016
- 2016-07-14 JP JP2017528720A patent/JP6669750B2/ja active Active
- 2016-07-14 WO PCT/JP2016/070796 patent/WO2017010537A1/fr not_active Ceased
- 2016-07-15 TW TW105122442A patent/TW201717952A/zh unknown

Also Published As

Publication number	Publication date
JP6669750B2 (ja)	2020-03-18
WO2017010537A1 (fr)	2017-01-19
JPWO2017010537A1 (ja)	2018-04-26

Publication	Publication Date	Title
TW201717952A (zh)	2017-06-01	含有環狀二肽的血清肉鹼分解酵素阻礙用組成物
JP6839080B2 (ja)	2021-03-03	動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物
TW201642896A (zh)	2016-12-16	脂肪酶抑制劑
JP6666912B2 (ja)	2020-03-18	Ｔｒｐｖ１刺激用組成物
TW201716079A (zh)	2017-05-16	Ｇｌｐ－２分泌促進用組成物
TW201733607A (zh)	2017-10-01	神經性疾病之預防用組成物
CN107922458B (zh)	2022-01-21	含有氨基酸及环状二肽的组合物
TW201733608A (zh)	2017-10-01	含有環狀二肽之神經性疾病之預防用組成物
JP6857602B2 (ja)	2021-04-14	エンドセリン受容体拮抗用組成物
JP2022023012A (ja)	2022-02-07	β－ラクトグロブリン由来ペプチドを含有する神経細胞死の抑制剤
TW201642895A (zh)	2016-12-16	α－葡萄糖苷酶抑制劑
TW201716067A (zh)	2017-05-16	含有環狀二胜肽之抗肥胖用組成物
JP6684277B2 (ja)	2020-04-22	レニン−アンジオテンシン系抑制用組成物
TW201717987A (zh)	2017-06-01	黑色素聚集激素受體拮抗用組成物
JP6786490B2 (ja)	2020-11-18	抗肥満用組成物
HK1250726B (zh)	2022-07-08	含有氨基酸及环状二肽的组合物